Exploiting evolutionary steering to induce collateral drug sensitivity in cancer

Ahmet Acar; Daniel Nichol; Javier Fernandez-Mateos; George D. Cresswell; Iros Barozzi; Sung Pil Hong; Nicholas Trahearn; Inmaculada Spiteri; Mark Stubbs; Rosemary Burke; Adam Stewart; Giulio Caravagna; Benjamin Werner; Georgios Vlachogiannis; Carlo C. Maley; Luca Magnani; Nicola Valeri; Udai Banerji; Andrea Sottoriva

doi:10.1038/s41467-020-15596-z

Exploiting evolutionary steering to induce collateral drug sensitivity in cancer

Ahmet Acar, Daniel Nichol, Javier Fernandez-Mateos, George D. Cresswell, Iros Barozzi, Sung Pil Hong, Nicholas Trahearn, Inmaculada Spiteri, Mark Stubbs, Rosemary Burke, Adam Stewart, Giulio Caravagna, Benjamin Werner, Georgios Vlachogiannis, Carlo C. Maley, Luca Magnani, Nicola Valeri, Udai Banerji, Andrea Sottoriva

Life Sciences, School of (SOLS)

Research output: Contribution to journal › Article › peer-review

59 Scopus citations

Abstract

Drug resistance mediated by clonal evolution is arguably the biggest problem in cancer therapy today. However, evolving resistance to one drug may come at a cost of decreased fecundity or increased sensitivity to another drug. These evolutionary trade-offs can be exploited using ‘evolutionary steering’ to control the tumour population and delay resistance. However, recapitulating cancer evolutionary dynamics experimentally remains challenging. Here, we present an approach for evolutionary steering based on a combination of single-cell barcoding, large populations of 10⁸–10⁹ cells grown without re-plating, longitudinal non-destructive monitoring of cancer clones, and mathematical modelling of tumour evolution. We demonstrate evolutionary steering in a lung cancer model, showing that it shifts the clonal composition of the tumour in our favour, leading to collateral sensitivity and proliferative costs. Genomic profiling revealed some of the mechanisms that drive evolved sensitivity. This approach allows modelling evolutionary steering strategies that can potentially control treatment resistance.

Original language	English (US)
Article number	1923
Journal	Nature communications
Volume	11
Issue number	1
DOIs	https://doi.org/10.1038/s41467-020-15596-z
State	Published - Dec 1 2020

ASJC Scopus subject areas

General Chemistry
General Biochemistry, Genetics and Molecular Biology
General Physics and Astronomy

Access to Document

10.1038/s41467-020-15596-z

Cite this

Acar, A., Nichol, D., Fernandez-Mateos, J., Cresswell, G. D., Barozzi, I., Hong, S. P., Trahearn, N., Spiteri, I., Stubbs, M., Burke, R., Stewart, A., Caravagna, G., Werner, B., Vlachogiannis, G., Maley, C. C., Magnani, L., Valeri, N., Banerji, U., & Sottoriva, A. (2020). Exploiting evolutionary steering to induce collateral drug sensitivity in cancer. Nature communications, 11(1), Article 1923. https://doi.org/10.1038/s41467-020-15596-z

Acar, A, Nichol, D, Fernandez-Mateos, J, Cresswell, GD, Barozzi, I, Hong, SP, Trahearn, N, Spiteri, I, Stubbs, M, Burke, R, Stewart, A, Caravagna, G, Werner, B, Vlachogiannis, G, Maley, CC, Magnani, L, Valeri, N, Banerji, U & Sottoriva, A 2020, 'Exploiting evolutionary steering to induce collateral drug sensitivity in cancer', Nature communications, vol. 11, no. 1, 1923. https://doi.org/10.1038/s41467-020-15596-z

@article{6e69861b124348e3a3eabae5f240fda8,

title = "Exploiting evolutionary steering to induce collateral drug sensitivity in cancer",

abstract = "Drug resistance mediated by clonal evolution is arguably the biggest problem in cancer therapy today. However, evolving resistance to one drug may come at a cost of decreased fecundity or increased sensitivity to another drug. These evolutionary trade-offs can be exploited using {\textquoteleft}evolutionary steering{\textquoteright} to control the tumour population and delay resistance. However, recapitulating cancer evolutionary dynamics experimentally remains challenging. Here, we present an approach for evolutionary steering based on a combination of single-cell barcoding, large populations of 108–109 cells grown without re-plating, longitudinal non-destructive monitoring of cancer clones, and mathematical modelling of tumour evolution. We demonstrate evolutionary steering in a lung cancer model, showing that it shifts the clonal composition of the tumour in our favour, leading to collateral sensitivity and proliferative costs. Genomic profiling revealed some of the mechanisms that drive evolved sensitivity. This approach allows modelling evolutionary steering strategies that can potentially control treatment resistance.",

author = "Ahmet Acar and Daniel Nichol and Javier Fernandez-Mateos and Cresswell, {George D.} and Iros Barozzi and Hong, {Sung Pil} and Nicholas Trahearn and Inmaculada Spiteri and Mark Stubbs and Rosemary Burke and Adam Stewart and Giulio Caravagna and Benjamin Werner and Georgios Vlachogiannis and Maley, {Carlo C.} and Luca Magnani and Nicola Valeri and Udai Banerji and Andrea Sottoriva",

note = "Publisher Copyright: {\textcopyright} 2020, The Author(s).",

year = "2020",

month = dec,

day = "1",

doi = "10.1038/s41467-020-15596-z",

language = "English (US)",

volume = "11",

journal = "Nature communications",

issn = "2041-1723",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - Exploiting evolutionary steering to induce collateral drug sensitivity in cancer

AU - Acar, Ahmet

AU - Nichol, Daniel

AU - Fernandez-Mateos, Javier

AU - Cresswell, George D.

AU - Barozzi, Iros

AU - Hong, Sung Pil

AU - Trahearn, Nicholas

AU - Spiteri, Inmaculada

AU - Stubbs, Mark

AU - Burke, Rosemary

AU - Stewart, Adam

AU - Caravagna, Giulio

AU - Werner, Benjamin

AU - Vlachogiannis, Georgios

AU - Maley, Carlo C.

AU - Magnani, Luca

AU - Valeri, Nicola

AU - Banerji, Udai

AU - Sottoriva, Andrea

PY - 2020/12/1

Y1 - 2020/12/1

N2 - Drug resistance mediated by clonal evolution is arguably the biggest problem in cancer therapy today. However, evolving resistance to one drug may come at a cost of decreased fecundity or increased sensitivity to another drug. These evolutionary trade-offs can be exploited using ‘evolutionary steering’ to control the tumour population and delay resistance. However, recapitulating cancer evolutionary dynamics experimentally remains challenging. Here, we present an approach for evolutionary steering based on a combination of single-cell barcoding, large populations of 108–109 cells grown without re-plating, longitudinal non-destructive monitoring of cancer clones, and mathematical modelling of tumour evolution. We demonstrate evolutionary steering in a lung cancer model, showing that it shifts the clonal composition of the tumour in our favour, leading to collateral sensitivity and proliferative costs. Genomic profiling revealed some of the mechanisms that drive evolved sensitivity. This approach allows modelling evolutionary steering strategies that can potentially control treatment resistance.

AB - Drug resistance mediated by clonal evolution is arguably the biggest problem in cancer therapy today. However, evolving resistance to one drug may come at a cost of decreased fecundity or increased sensitivity to another drug. These evolutionary trade-offs can be exploited using ‘evolutionary steering’ to control the tumour population and delay resistance. However, recapitulating cancer evolutionary dynamics experimentally remains challenging. Here, we present an approach for evolutionary steering based on a combination of single-cell barcoding, large populations of 108–109 cells grown without re-plating, longitudinal non-destructive monitoring of cancer clones, and mathematical modelling of tumour evolution. We demonstrate evolutionary steering in a lung cancer model, showing that it shifts the clonal composition of the tumour in our favour, leading to collateral sensitivity and proliferative costs. Genomic profiling revealed some of the mechanisms that drive evolved sensitivity. This approach allows modelling evolutionary steering strategies that can potentially control treatment resistance.

UR - http://www.scopus.com/inward/record.url?scp=85083774989&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85083774989&partnerID=8YFLogxK

U2 - 10.1038/s41467-020-15596-z

DO - 10.1038/s41467-020-15596-z

M3 - Article

C2 - 32317663

AN - SCOPUS:85083774989

SN - 2041-1723

VL - 11

JO - Nature communications

JF - Nature communications

IS - 1

M1 - 1923

ER -

Exploiting evolutionary steering to induce collateral drug sensitivity in cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this